CD44 and cancer: In studies involving human head and neck squamous cell cancer under deferoxamine-induced hypoxia, OXY pre-treatment inhibited cancer stem cell markers such as Oct-4, Nanog, CD-44, and CD-105, suggesting that OXY may prevent the epithelial–mesenchymal transition (EMT) and metastasis [43].